Dubermatinib tartrate is under clinical development by Sumitomo Dainippon Pharma Oncology and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I drugs for Metastatic Melanoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Dubermatinib tartrate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dubermatinib tartrate overview
Dubermatinib tartrate (TP-0903, HCI-2084) is under development for the treatment of metastatic solid tumors including non-small cell lung cancer, colorectal cancer, melanoma, ovarian cancer, breast cancer, head and neck cancer, hematological tumors including acute myeloid leukemia, T-cell acute lymphoblastic leukemia (T-ALL), and acute myelocytic leukemia. It is a small molecule administered orally. The drug candidate acts by targeting Axl Kinase. It was also under development for the treatment of chronic lymphocytic leukemia.
Sumitomo Dainippon Pharma Oncology overview
Sumitomo Dainippon Pharma Oncology (Sumitomo Dainippon), formerly Boston Biomedical, a subsidiary of Sumitomo Chemical Co Ltd, is a developer of novel therapeutics to treat cancer. The company offers drug discovery, crystallography, medicinal chemistry, preclinical development, pharmacology, pharmaceutical development, clinical trials, and regulatory affair services. Its drug candidates include BBI608 and BBI503. The company also offers cancer stem cell development programs that include cancer cell stemless, signaling pathways, treatment resistance, recurrence and metastasis; resources and CSC programs. Sumitomo Dainippon is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of Dubermatinib tartrate’s drug-specific PTSR and LoA scores, buy the report here.